Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as BMS-641988 (AR#2)
BMS-641988 · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A1 | EXPERIMENTAL | Active |
| Name | Type | Description |
|---|---|---|
| BMS-641988 (AR#2) | DRUG | Tablets, Oral, 20 mg, 40 mg, 60 mg, 100 mg, once daily, 24 weeks |
Inclusion Criteria: * Patients with castration-resistant prostate cancer and serum testosterone ≤50 ng/dL progressive to current therapy who satisfy the inclusion and exclusion criteria
Top 20 of 55 competitors
BMS-641988 is an investigational small molecule developed by Bristol-Myers Squibb for the treatment of prostate cancer. It was studied in a Phase 1 clinical trial in Japanese patients with castration resistant prostate cancer. It is not an approved medicine and remains an experimental agent in clinical development.
BMS-641988 was studied for castration resistant prostate cancer, an advanced form of prostate cancer that continues to progress despite androgen deprivation therapy. The single Phase 1 trial enrolled Japanese men with this condition. No approved use has been established for BMS-641988.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, developed BMS-641988. The company sponsored the Phase 1 study of the compound in Japanese patients with castration resistant prostate cancer.
BMS-641988 is in Phase 1 development. One Phase 1 trial has been completed, and no trials are currently active. The study was an uncontrolled, open-label dose evaluation rather than a randomized or double-blind design, and it enrolled seven patients.
BMS-641988 was evaluated in one completed Phase 1 trial, NCT00644488, titled A Phase I Study of BMS-641988 in Japanese Patients With Castration Resistant Prostate Cancer. The trial enrolled seven men aged 20 years and older in Japan and is listed as completed.
Yes. BMS-641988 is also referred to as BMS-641988 (AR#2). Both names refer to the same investigational Bristol-Myers Squibb compound studied in castration resistant prostate cancer, so searches under either name point to the same drug asset.